Clinical Trials Logo

Filter by:
NCT ID: NCT06439277 Not yet recruiting - Obesity Clinical Trials

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.

NCT ID: NCT06435247 Not yet recruiting - Old Age; Debility Clinical Trials

The Effect of Accompainment by Older Adults on Anesthetic Recovery

AAR
Start date: June 2024
Phase: N/A
Study type: Interventional

Summary: In 2022, Mexico estimated a population of 17,958,707 older adults. With increased life expectancy, it is essential to seek strategies that improve the health of this population, as they are more vulnerable compared to other age groups due to functional and cognitive decline, along with an increase in chronic diseases and medication intake. During this stage of life, there is a possibility of requiring surgical treatment, which is the focus of this protocol proposing a maneuver that impacts patients' health without requiring economic costs. The proposal suggests the accompaniment of older adults by a family member during the immediate post-anesthetic period. Hypothesis: Accompaniment of older adults during the immediate postoperative period improves the quality of anesthetic recovery by 60%. This value is based on a study by Shem, where accompanying older adults prior to anesthetic induction resulted in a 61% reduction in anxiety among older adults. Anesthesiologists have expanded their role in perioperative medicine alongside geriatric medicine services for older surgical patients. An experimental study will be conducted with two randomly divided groups: one group with accompaniment and one group without accompaniment in the recovery area. Both groups will be assessed using different questionnaires: 1. Pfeiffer Test for cognitive impairment diagnosis, 2. QoR-15 to assess the quality of anesthetic recovery, 3. Beck Anxiety Questionnaire, all of which will be administered 24 hours after surgery. Delirium will also be assessed using NuDESC at 24 hours, day 5, and 30 days after surgery. General data prior to surgery will be recorded, and vital signs such as heart rate, blood pressure, and pain on a verbal scale from 0 to 10 will be monitored during the postoperative period. Statistical analysis will involve representing baseline characteristics of the population using mean and standard deviation or median and interquartile range, depending on the distribution type. X2 will be used to compare both groups in terms of outcomes. Finally, a multivariate analysis will be conducted using logistic regression to adjust for confounding variables.

NCT ID: NCT06432816 Recruiting - Menopause Clinical Trials

Efficacy of Nano-Pso Therapy in Menopause

Start date: February 28, 2024
Phase: N/A
Study type: Interventional

Vasomotor syndrome is prevalent in 85% of postmenopausal women, hormone therapy in menopause is first-line therapy, but 38% of patients have some contraindication for its use. The medications indicated in this population presents adverse reactions, such as dryness of the mucous membranes, and insomnia in patients, and triggers to abandoned treatment due to poor response to the drug. Aligned with the safety of patients, we wish to test pomegranate seed oil with nanotechnology (NANOPSO), which has been reported to have positive results at a central level, due to its antioxidant effect, which could impact women in climacteric in a positive way. The study involves the participation of 90 patients divided into two groups, where placebo or Nano-PSO will be administered for 60 days, with a total follow-up of 120 days. It is established that patients must not have received previous treatments for menopausal symptoms. Therefore, it is expected that therapy with NANO-PSO compared to placebo will be more effective in controlling vasomotor symptoms in early menopause after 6 months of treatment evaluated by the MRS scale.

NCT ID: NCT06428266 Completed - Clinical trials for Lacrimal Duct Obstruction

Closed Dacryointubation vs Bicanalicular Intubation for Proximal Tear Duct Obstruction

DICvsBIcanal
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

In Mexico, upper lacrimal duct obstruction (ULDO) is a common pathology, and the standard surgical treatment is closed dracryointubation. Based on statistics from our headquarters, in 30% of cases there is a failure of the technique and recurrence of symptoms due to associated complications. Because of this, the application of a self-stable bicananlicular intubation set is proposed. The aim of this study is to describe the difference in efficacy and complication rate between the application of the self-stable bicanalicular intubation set II (FCI) and closed dacryointubation in patients with ULDO .

NCT ID: NCT06425224 Recruiting - Clinical trials for Premature Ejaculation

Effectiveness and Safety of TENS Therapy for Premature Ejaculation

TENSPE2
Start date: June 15, 2022
Phase: Phase 3
Study type: Interventional

The objective of this clinical trial is to evaluate the effectiveness and safety of transcutaneous posterior tibial nerve stimulation therapy in patients with premature ejaculation. The main question to answer is: Can the effectiveness and safety of transcutaneous electrostimulation of the posterior tibial nerve alone and combined with standard pharmacological treatment be evaluated in men with lifelong premature ejaculation, compared to standard pharmacological treatment with dapoxetine? Patients will: Be randomized in acontrolled clinical trial. Patients with a diagnosis of premature ejaculation who attend Boston Medical Group clinics in Mexico City will be included. Be assigned by randomization to one of three treatment groups: - Group 1: Tens therapy + dapoxetine placebo on demand. - Group 2: Standard treatment (dapoxetine 30 mg as needed) + placebo therapy. - Group 3: Tens therapy + standard treatment (dapoxetine 30 mg as needed).

NCT ID: NCT06422884 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Start date: September 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in these patient populations.

NCT ID: NCT06422533 Recruiting - Neutropenia Clinical Trials

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Start date: November 7, 2023
Phase: N/A
Study type: Interventional

Patients with hematological malignancies receive highly myelotoxic chemotherapy regimens that cause periods of severe myelosuppression, which places them at high risk of developing bacteremia. At a global level, a very significant increase in multidrug-resistant (MDR) Gram-negative microorganisms, particularly Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL) and MDR P.aeruginosa, have been described during the last decade. Among the strategies to reduce bacterial resistance, ceftolozane/tazobactam (C/T) as a "carbapenem-sparing" antibiotic has been proposed. C/T has broad-spectrum activity since it has action against ESBL-producing Enterobacteriaceae and MDR P. aeruginosa. Studies carried out in the real world using this antibiotic in patients with hematological malignancies have demonstrated clinical success in reports and case series, considered a therapeutic option in patients with Enterobacteriaceae and P. aeruginosa infections, particularly in MDR pathogens. At the National Cancer Institute (in Spanish, Instituto Nacional de Cancerologia), Gram-negative bacilli have been identified for more than 20 years as the pathogens most frequently associated with bacteremia. Escherichia coli occupies the first place in 25% (41% ESBL), followed by Klebsiella spp. in 5.6% (11.2% ESBL) and P. aeruginosa in 5.6% (11.2% MDR). The protocol for approaching and treating hematological malignancy patients with severe neutropenia and fever is to initiate an antimicrobial regimen with piperacillin/tazobactam (P/T). In patients who persist with fever after 48 to 72 hours of starting antibiotics, who present with clinical deterioration, or in whom P/T-resistant bacteria are identified, this is escalated to carbapenem. Therefore, it is proposed to compare the clinical and microbiological response in patients with hematological malignancies who present with severe neutropenia and fever and who present clinical data of bacteremia, with empirical treatment with C/T vs. P/T, trying to reduce the use of carbapenems in this group of patients.

NCT ID: NCT06419712 Completed - Clinical trials for Post-COVID19 Condition

Effect of Vitamin D Supplementation on Glutathione Peroxidase (GPx) Activity, Interleukin-6 (IL-6) Levels and Clinical Outcomes in Post-COVID-19 Patients

VITDPOSTCOVID
Start date: November 25, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness of vitamin D supplementation in treating neuropsychiatric symptoms and improving antioxidant levels in individuals diagnosed with post-COVID-19 condition, a state known as long-COVID. These individuals are primarily adults who have recovered from severe COVID-19 and exhibit persistent symptoms. The main questions it aims to answer are: Does vitamin D (cholecalciferol) supplementation decrease levels of anxiety and depression in patients with post-COVID-19 condition? Does vitamin D (cholecalciferol) supplementation increase glutathione peroxidase (GPx) activity in these patients? Researchers will compare the effects of daily versus bolus doses of vitamin D (cholecalciferol) to see if one method is more effective than the other in achieving sufficient vitamin D levels and improving clinical outcomes. Participants will: Be randomly assigned to receive either a daily dose or a bolus dose of vitamin D over an 8-week period. Undergo blood tests to measure biochemical markers such as interleukin-6 (IL-6) and GPx before and two months after starting supplementation. Have their lung function tested using spirometry and diffusing capacity for carbon monoxide. Complete the Hospital Anxiety and Depression Scale to assess changes in anxiety and depression levels.

NCT ID: NCT06416124 Completed - Athletes Clinical Trials

Anthropometric Characteristics of Elite and Olympic Mexican Track and Field Athletes

ANTHROLYMPMX
Start date: July 5, 2013
Phase:
Study type: Observational

Sport specialization requires an understanding of morphological variability to optimize performance. However, the current literature lacks a detailed analysis of the anthropometric profile of track and field athletes, especially in Latin America. Additionally, the five-way fractionation method of body mass has been under-documented. These gaps highlight the need for more research to maximize the potential of athletes, particularly in emerging countries like Mexico. This study aims to determine the anthropometric characteristics of elite and Olympic Mexican track and field athletes. A descriptive cross-sectional study will be conducted. Forty-three anthropometric variables will be assessed to characterize the athlete´s physical composition using the standards of the International Society for the Advancement of Kinanthropometry (ISAK). Those variables will be used to describe the anthropometric profile (Heath and Carter somatotype, body composition through five-way fractionation method, muscle bone index, muscular adipose index, sum of skinfold thicknesses, and proportionality through Ross & Wilson Phantom strategy. Correspondences of those variables will also be established among different tests and specialties: sprint, middle-distance, long-distance, endurance, combined events, jumps, and throws. This study aims to provide the opportunity to generate reliable references for high-performance Mexican athletes.

NCT ID: NCT06411249 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

BE-EARLY
Start date: June 4, 2024
Phase: Phase 4
Study type: Interventional

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.